The ACE2 Lentivirus is replication incompetent, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. Under the control of EF1a promoter the particles contain an ACE2 gene (NM_021804.3) allowing transient expression of ACE2 in your target cell or a generation of a stable cell line expressing ACE2 using Puromycin.

Due to its interaction with the Human ACE2 , the coronavirus Spike protein is involved in the first step of the viral replication which is the attachment of the virus to the host cell. To advance research of this Spike:ACE2 interaction, BPS Bioscience has developed the Spike (SARS-CoV-2) Pseudotyped Lentivirus. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, to easily measure spike-mediated entry into target cells via luciferase reporter activity. The Spike protein includes the entire extracellular domain to allow studies of S1-S2 cleavage as well as receptor binding.

The Bald Lentiviral Pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the firefly luciferase gene driven by a CMV promoter as the reporter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.